Investigational drug · Phase 3
Salanersen
Also called: BIIB115
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Muscular Atrophy, Spinal, Spinal Muscular Atrophy.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "Salanersen"
First trial start
2026
Apr 28, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Salanersen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Muscular Atrophy, Spinal
- Spinal Muscular Atrophy
Approved drugs for the same conditions: Spinal muscular atrophy · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Salanersen" as an intervention, largest first.
BiogenBiogen (BIIB)
NCT07444476 · 90 participants (planned) · Start Sep 8, 2026 · Primary completion Jun 23, 2028
Drug: Salanersen · For: Spinal Muscular Atrophy
Sites: Palo Alto, California; Boston, Massachusetts; Norfolk, Virginia · 12 sites in all
- A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene AbeparvovecPivotal-lookingRecruiting
BiogenBiogen (BIIB)
NCT07444450 · 42 participants (planned) · Start Oct 31, 2026 · Primary completion Jul 27, 2029
Drug: Salanersen · For: Muscular Atrophy, Spinal
Sites: Flower Mound, Texas
- A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)Pivotal-lookingRecruiting
BiogenBiogen (BIIB)
NCT07221669 · 30 participants (planned) · Start Apr 28, 2026 · Primary completion Nov 28, 2028
Drug: Salanersen · For: Muscular Atrophy, Spinal
Sites: Chicago, Illinois; Flower Mound, Texas; Norfolk, Virginia · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Enhanced splicing modulation by NMA-modified antisense oligonucleotides.
Ling K, Prakash TP, Yu J, et al. · Nucleic Acids Res 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Biogen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.